ERBB2 and breast carcinoma: Although formal guidelines specific to PTEN assessment are not as established as those for other breast cancer biomarkers, such as hormone receptors, HER2, or PD-L1, laboratories are encouraged to implement rigorous quality control measures similar to those recommended for other IHC assays [75–78].